When used in pre-dialysis CKD patients, it showed that PTH was suppressed as 25(OH)D levels reached at least 50.8 ng/mL; moreover, elevation to 92.5 ng/mL was not associated with adverse events, indicating that targets for vitamin D repletion therapy in CKD might be higher [20]. This evidence concerns the gene PTH and chronic kidney disease.